SHANGHAI, CHINA -- (MARKET WIRE) -- April 24, 2007 -- SinoBiomed Inc. (“SinoBiomed”, “the Company”) (OTCBB: SOBM) is pleased to announce that the United States Patent and Trademark office has granted a patent for the malaria vaccine PfCP2.9 to which SinoBiomed has exclusive rights to develop, manufacture and sell through its 82 percent owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co. Ltd. (“Shanghai Wanxing”).
